HK Stock Market Move | SMOORE INTL (06969) rises over 5%; the company achieved steady profit growth in Q3; a major client's flavored vape products have been launched in the US.
SMOORE INTL (06969) rose over 5%. As of press time, it was up 4.86% at HK$8.41, with a turnover of HK$24.2125 million.
SMOORE INTL (06969) rose over 5%, up 4.86% as of press time, at HK$8.41, with a turnover of HK$24.2125 million.
On the news front, SMOORE INTL recently disclosed its Q3 results. In the first three quarters of 2026, the company achieved revenue of RMB 11.155 billion, up 9.3% year-on-year, and adjusted net profit of RMB 1.209 billion, up 2.3% year-on-year; excluding the temporary impact of losses from the atomization medical business, adjusted net profit was RMB 1.384 billion, up 2.6% year-on-year. Among them, 26Q3 achieved revenue of RMB 3.946 billion, down 6.0% year-on-year, and adjusted net profit of RMB 452 million, up 1.8% year-on-year. Huatai believes that the year-on-year decline in the company's Q3 revenue was mainly due to the high base of both the atomization and HNB businesses in the same period last year; however, benefiting from improved product mix and lower expenses, Q3 profit achieved steady growth.
Huatai pointed out that in 26Q3, the company's atomization segment achieved revenue of RMB 3.454 billion, up 2.5% year-on-year. On the to B side, 26Q3 electronic atomization and special-purpose revenue was RMB 2.651 billion, up 1.8% year-on-year, mainly driven by performance in the US market; total revenue for the first three quarters was RMB 7.452 billion, up 6.5% year-on-year. The implementation of the disposable e-cigarette ban in Europe is conducive to reshaping the industry's competitive landscape, and the company continues to strengthen cooperation with high-value customers to expand the market; positive changes in US regulatory policy are favorable to compliant large tobacco companies, and the company began delivering flavored vape products to its core major client in Q3, which have been launched in the terminal market, with future performance worth anticipating.
Related Articles

BUTONG GROUP (06090) repurchased 110,000 shares for HK$3.8656 million on October 15.

LEADS BIOLABS-B(09887): First Patient Dosed in Phase IB/II Clinical Trial of Vilixin (Opatilimab, PD-L1/41BB Bispecific Antibody) in Combination Therapy for Metastatic Colorectal Cancer

AI hot money flows to upstream miners: Tech giants want to "take stakes" in Anglo American, BHP Group Ltd Sponsored American Depositary Receipt Repr 2 Shs(BHP.US) and other mining companies to lock in copper supply.
BUTONG GROUP (06090) repurchased 110,000 shares for HK$3.8656 million on October 15.

LEADS BIOLABS-B(09887): First Patient Dosed in Phase IB/II Clinical Trial of Vilixin (Opatilimab, PD-L1/41BB Bispecific Antibody) in Combination Therapy for Metastatic Colorectal Cancer

AI hot money flows to upstream miners: Tech giants want to "take stakes" in Anglo American, BHP Group Ltd Sponsored American Depositary Receipt Repr 2 Shs(BHP.US) and other mining companies to lock in copper supply.






